Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.athoracsur.2024.06.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of Trial Eligibility Criteria on Outcomes of 1183 Patients With Follicular Lymphoma Treated in the Real-World Setting.
Eur J Haematol
January 2025
Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark.
The development of new first-line treatments for patients with follicular lymphoma (FL) is becoming increasingly challenging due to already excellent survival outcomes. The present study investigated the outcomes of patients with FL who underwent contemporary first-line therapies but would not have been eligible for inclusion in recent trials and explored how commonly used in/exclusion criteria impacted their survival outcomes. This study included adult patients diagnosed with FL in the period 2000-2018 registered in the Danish Lymphoma Registry.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Background: Drugs targeting Alzheimer's disease (AD) pathology are likely to be most effective in the presymptomatic stage, where individuals harbor AD pathology but have not manifested symptoms. Neuroimaging approaches can help to identify such individuals, but are costly for population-wide screening. Cost-effective screening is needed to identify those who may benefit from neuroimaging, such as those at risk of developing clinical disease.
View Article and Find Full Text PDFBackground: The extracellular deposition of amyloid-beta (Aβ) and intracellular aggregation of hyperphosphorylated tau proteins stand as histopathological hallmarks of Alzheimer's disease (AD). The spatial-temporal relationship between the Aβ pathway and tau pathophysiology in AD, plays a crucial role in comprehending the pathogenesis and progression of AD. Understanding the interrelationship between Aβ and tau, is crucial to elucidate the failure of previous therapeutic strategies and understanding AD progression and will inform the next generation of clinical trials.
View Article and Find Full Text PDFDeveloping Topics.
Alzheimers Dement
December 2024
Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, CA, USA.
Background: Most hospice-eligible patients with dementia report agitation with antipsychotics and antidepressants with major side effects predominantly used in this population to control symptoms. Little is known about current evidence on randomized controlled trials (RCTs) on reducing agitation in this population.
Objectives: We aimed to summarize and evaluate the existing literature on RCTs aimed at reducing agitation among hospice-eligible patients with dementia.
Five-year comparison of clinical and echocardiographic outcomes of pure aortic stenosis with pure aortic regurgitation or mixed aortic valve disease in the COMMENCE trial.
JTCVS Open
December 2024
Department of Cardiovascular Surgery, Jefferson Health, Philadelphia, Pa.
Objective: To compare outcomes of aortic valve replacement (AVR) in patients with pure aortic stenosis (Pure AS) and those with pure aortic regurgitation (Pure AR) or mixed AS and AR (MAVD) in the COMMENCE trial.
Methods: Of 689 patients who underwent AVR in the COMMENCE trial, patients with moderate or severe AR with or without AS (Pure AR + MAVD; n = 135) or Pure AS (n = 323) were included. Inverse probability of treatment weighting Kaplan-Meier survival curves were used for time-to-event endpoints, and longitudinal changes in hemodynamics were evaluated using mixed-effects models.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!